van Dijk AD, Hoff FW, Qiu Y, Gerbing RB, Gamis AS, Aplenc R, Kolb EA, Alonzo TA, Meshinchi S, Jenkins GN, de Bont ESJM, Kornblau SM, Horton TM. Bortezomib is significantly beneficial for de novo pediatric AML patients with low phosphorylation of the NF-κB subunit RelA. Proteomics Clin Appl. 2022 Mar;16(2):e2100072. doi: 10.1002/prca.202100072. Epub 2021 Nov 17. PubMed PMID: 34719869; PubMed Central PMCID: PMC9041833.
